Myriad Genetics, Inc. (MYGN)

19.47 -0.10 (-0.51%) 收市：04:00PM EDT

Myriad Genetics, Inc.

322 North 2200 West
Salt Lake City, UT 84116
United States
801 584 3600
https://www.myriad.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 2,700

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Paul J. Diaz	CEO, President & Director	2.31M	無	1962
Mr. Samraat S. Raha	Chief Operating Officer	514.76k	無	1973
Dr. Dale Muzzey Ph.D.	Chief Scientific Officer	816.5k	無	1980
Mr. Mark S. Verratti	Chief Commercial Officer	915.81k	無	1968
Mr. Scott J. Leffler	Chief Financial Officer	無	無	1975
Ms. Natalie Munk	Principal Accounting Officer	無	無	1981
Dr. Kevin Richard Haas Ph.D.	Chief Technology Officer	580.36k	無	1986
Mr. Matthew Scalo	Senior Vice President of Investor Relations	無	無	無
Mr. Glenn Farrell	Senior VP & Chief Marketing Officer	無	無	無
Ms. Shereen Solaiman	Chief People Officer	無	無	1973

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

公司管治

截至 2024年4月29日 止，Myriad Genetics, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：10；董事會：1；股東權利：5；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。